TP53 and neoplasm: In the present study, we evaluated whether gene therapy with rAdV-ASPP2, rAdV-p53, and rAdV-TK/GCV is more effective than gene therapy with rAdV-TK/GCV alone for the induction of tumor death with and without functional p53.